Pediatric hematology oncology in Brazil

Camargo, Beatriz de; Kurashima, Andréa Yamaguchi

doi:10.1002/pbc.22223

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2007, a study showed that tumor specimens from 20 out of 100 patients with osteosarcoma were KIT-positive and that OS were not different between patients with and without KIT expression (85). In 2011, another study found that KIT was expressed in 46.15% patients with osteosarcoma and that KIT-positive tumors had worse response to chemotherapy (86). The results of both studies point to the possibility that KIT is not a key player in proliferation and metastasis of osteosarcoma.…”

Section: Kitmentioning

confidence: 99%

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

2020

View full text Add to dashboard Cite

Recent clinical trials have shown several multi-target tyrosine kinase inhibitors (TKIs) to be effective in the treatment of osteosarcoma. However, these TKIs have a number of targets, and it is yet unclear which of these targets has a key role in osteosarcoma treatment. In this review, we first summarize the TKIs that were studied in clinical trials registered on ClinicalTrials.gov. Further, we compare and discuss the targets of these TKIs. We found that TKIs with promising therapeutic effect for osteosarcoma include apatinib, cabozantinib, lenvatinib, regorafenib, and sorafenib. The key targets for osteosarcoma treatment may include VEGFRs and RET. The receptor tyrosine kinases (RTKs) MET, IGF-1R, AXL, PDGFRs, KIT, and FGFRs might be relevant but unimportant targets for osteosarcoma treatment. Inhibition of one type of RTK for the treatment of osteosarcoma is not effective. It is necessary to inhibit several relevant RTKs simultaneously to achieve a breakthrough in osteosarcoma treatment. This review provides comprehensive information on TKI targets relevant in osteosarcoma treatment, and it will be useful for further research in this field.

show abstract

Section: Kitmentioning

confidence: 99%

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

2020

View full text Add to dashboard Cite

show abstract

“…Esses pediatras percebem a necessidade de se especializar na área e recorrem a instituições internacionais para isso. Em 1976, o Hospital A. C. Camargo cria um programa de bolsa para formação médica na área (Camargo & Kurashima, 2009 Percebe-se que a especialidade de oncologia pediátrica é contemporânea e tem seu corpo de conhecimento e prática em processo de construção. (Mutti, Paula & Souto, 2010).…”

Section: Inserção No Brasilunclassified

Sobreviventes de câncer infanto-juvenil: contribuições da psicanálise e novos dispositivos clínicos

Almeida¹

View full text Add to dashboard Cite

Tenho medo de escrever. É tão perigoso. Quem tentou sabe. Perigo de mexer no que está ocultoe o mundo não está à tona, está oculto em suas raízes submersas em profundidade do mar. Para escrever tenho que me colocar no vazio. Neste vazio é que existo intuitivamente. Mas é um vazio terrivelmente perigoso: dele arranco sangue. Sou um escritor que tem medo da cilada das palavras: as palavras que digo escondem outrasquais? Talvez as diga. Escrever é uma pedra lançada no fundo do poço. Clarice Lispector (1999, p. 15).

show abstract

Indian Pediatric Oncology Group (InPOG) – Collaborative research in India comes of age

Arora

Bakhshi

2016

Pediatric Hematology Oncology Journal

View full text Add to dashboard Cite

Pediatric hematology oncology in Brazil

Cited by 4 publications

References 9 publications

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

Sobreviventes de câncer infanto-juvenil: contribuições da psicanálise e novos dispositivos clínicos

Indian Pediatric Oncology Group (InPOG) – Collaborative research in India comes of age

Contact Info

Product

Resources

About